Brief: Lundbeck And Otsuka Announce FDA Acceptance Of SNDA Filing For Brexpiprazole
June 25 (Reuters) - H Lundbeck A/S HLUNb.CO :
* H. LUNDBECK A/S: LUNDBECK AND OTSUKA ANNOUNCE FDA
ACCEPTANCE OF
SNDA FILING FOR BREXPIPRAZOLE IN COMBINATION WITH SERTRALINE FOR
THE TREATMENT OF ADULTS WITH POST-TRAUMATIC STRESS DISORDER
(PTSD)
Source text: https://mfn.se/cis/a/lundbeck/h-lundbeck-a-s-lundbeck-and-otsuka-announce-fda-acceptance-of-snda-filing-for-brexpiprazole-in-combination-with-sertraline-for-the-treatment-of-adults-with-post-traumatic-stress-disorder-ptsd-04865808
Further company coverage: HLUNb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options